Nycomed Amersham submits Sonazoid in Europe:
This article was originally published in Clinica
Executive Summary
UK company Nycomed Amersham has submitted Sonazoid, its ultrasound contrast agent for cardiology and radiology applications to the European Medicines Evaluation Agency for approval. The agent has already been submitted to the US FDA and the company is also investigating the use of Sonazoid in myocardial perfusion imaging.